Scoping review – What do we know about Aboriginal peoples’ use of dose administration aids?

Walke, Emma; Barclay, Lesley; Longman, Jo

doi:10.1002/hpja.577

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there is insufficient evidence to demonstrate whether there is a significant difference in medication adherence between Indigenous Australians and the general population, healthcare professionals believe adherence is a significant issue for Indigenous Australians [ 38 ]. Furthermore, a recent review noted a lack of empirical evidence regarding medication-taking behaviours among Indigenous Australians [ 39 ]. Further work is required to explore contributing factors to adherence issues in this population, however, these may include previously identified challenges such as misconceptions regarding medications and lack of culturally appropriate information sources [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

Medication-related problems identified by community pharmacists: a descriptive case study of two Australian populations

Collins,

Hu,

McMillan

et al. 2023

J of Pharm Policy and Pract

View full text Add to dashboard Cite

Background Medication-related problems (MRPs) contribute significantly to preventable patient harm and global healthcare expenditure. Vulnerable populations, including Indigenous Australians (please note that the use of the term ‘Indigenous’ in this paper includes all Aboriginal and Torres Strait Islander people and acknowledges their rich traditions and heterogenous cultures.) and people living with severe and persistent mental illness (SPMI), may be at increased risk of MRPs. Pharmacist-led medication reviews can identify MRPs for targeted action. Objective To characterize MRPs identified and recommendations made by community pharmacists during medication reviews conducted with Indigenous Australians and people living with SPMI. Methods Participants were recruited through two Australian trials testing the feasibility and/or effectiveness of novel community pharmacist-led interventions, the Indigenous Medication Review Service (IMeRSe) feasibility study (June 2018–July 2019) and Bridging the Gap between Physical and Mental Illness in Community Pharmacy (PharMIbridge) randomized controlled trial (September 2020–December 2021). Trained community pharmacists conducted medication reviews responsive to the cultural and health needs of participants. MRPs, MRP severity and pharmacist recommendations were documented and classified using an established classification system (DOCUMENT). MRP severity was assessed by pharmacists and an independent assessor. Data were analysed descriptively, and paired t-tests were used to compare severity ratings. Results Pharmacists identified 795 MRPs with 411 participants across both trials (n = 255 IMeRSe, n = 156 PharMIbridge). Non-adherence to medication was the most common (n = 157, 25.1%) and second-most common (n = 25, 14.7%) MRP in IMeRSe and PharMIbridge, respectively. Undertreatment was the second-most common MRP in the sample of Indigenous Australians (n = 139, 22.2%), and reports of toxicity/adverse reactions were most common in people living with SPMI (n = 41, 24.1%). A change in pharmacotherapy was the most frequent recommendation made by pharmacists (40.2% and 55.0% in IMeRSe and PharMIbridge, respectively). Severity ratings varied, with the majority being ‘Mild’ or ‘Moderate’ in both groups. Significant differences were found in the severity rating assigned by trial pharmacists and the independent assessor. Conclusions Community pharmacists identified a range of MRPs experienced by two at-risk populations, most commonly non-adherence and toxicity or adverse reactions, when conducting medication reviews and proposed diverse strategies to manage these, frequently recommending a change in pharmacotherapy. These findings highlight the opportunity for more targeted approaches to identifying and managing MRPs in primary care and tailored community pharmacist-led interventions may be of value in this space. Trail Registration: Australian and New Zealand Clinical Trial Registry records (IMeRSe ACTRN12618000188235 registered 06/02/2018 & PharMIbridge ACTRN12620000577910 registered 18/05/2020).

show abstract